Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phillip Scheinberg

Showing results (91-100 of 130) with videos related to

Pageof 13
Sort By:
The New England Journal of Medicine|April 20, 2017
Eltrombopag Added to Standard Immunosuppression for Aplastic AnemiaDanielle M Townsley, Phillip Scheinberg, Thomas Winkler, et al.
Blood Advances|December 18, 2024
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response ratesAna Rita da Fonseca, Caio Cesar Justino, Vinicius Campos de Molla, et al.
Blood|November 25, 2010
T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapyElaine M Sloand, J Joseph Melenhorst, Zachary C G Tucker, et al.
Journal of Immunological Methods|August 5, 2008
Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramersJ Joseph Melenhorst, Phillip Scheinberg, Pratip K Chattopadhyay, et al.
Blood|April 18, 2019
Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopagThomas Winkler, Xing Fan, James Cooper, et al.
Orphanet Journal of Rare Diseases|July 20, 2024
Clinical and genetic profiles of patients with hereditary and wild-type transthyretin amyloidosis: the Transthyretin Cardiac Amyloidosis Registry in the state of São Paulo, Brazil (REACT-SP)Fábio Fernandes, Georgina Del Cisne Jadán Luzuriaga, Guilherme Wesley Peixoto da Fonseca, et al.
The New England Journal of Medicine|May 19, 2016
Danazol Treatment for Telomere DiseasesDanielle M Townsley, Bogdan Dumitriu, Delong Liu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 2, 2010
Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010Michael A Pulsipher, Neal S Young, Jakub Tolar, et al.
British Journal of Clinical Pharmacology|January 21, 2025
Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuriaValérie Cosson, Rong Fu, Austin Kulasekararaj, et al.
Journal of Clinical Medicine|December 11, 2025
A Distinct Intestinal Domination Fingerprint in Patients Undergoing Allo-HSCT: Dynamics, Predictors and Implications on Clinical OutcomesAlexandre Soares Ferreira Junior, Danielle Amanda Niz Alvarez, Larissa da Silva Souza, et al.
Pageof 13

Showing results (91-100 of 130) with videos related to

Sort By:
Pageof 13
The New England Journal of Medicine|April 20, 2017
Eltrombopag Added to Standard Immunosuppression for Aplastic AnemiaDanielle M Townsley, Phillip Scheinberg, Thomas Winkler, et al.
Blood Advances|December 18, 2024
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response ratesAna Rita da Fonseca, Caio Cesar Justino, Vinicius Campos de Molla, et al.
Blood|November 25, 2010
T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapyElaine M Sloand, J Joseph Melenhorst, Zachary C G Tucker, et al.
Journal of Immunological Methods|August 5, 2008
Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramersJ Joseph Melenhorst, Phillip Scheinberg, Pratip K Chattopadhyay, et al.
Blood|April 18, 2019
Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopagThomas Winkler, Xing Fan, James Cooper, et al.
Orphanet Journal of Rare Diseases|July 20, 2024
Clinical and genetic profiles of patients with hereditary and wild-type transthyretin amyloidosis: the Transthyretin Cardiac Amyloidosis Registry in the state of São Paulo, Brazil (REACT-SP)Fábio Fernandes, Georgina Del Cisne Jadán Luzuriaga, Guilherme Wesley Peixoto da Fonseca, et al.
The New England Journal of Medicine|May 19, 2016
Danazol Treatment for Telomere DiseasesDanielle M Townsley, Bogdan Dumitriu, Delong Liu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 2, 2010
Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010Michael A Pulsipher, Neal S Young, Jakub Tolar, et al.
British Journal of Clinical Pharmacology|January 21, 2025
Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuriaValérie Cosson, Rong Fu, Austin Kulasekararaj, et al.
Journal of Clinical Medicine|December 11, 2025
A Distinct Intestinal Domination Fingerprint in Patients Undergoing Allo-HSCT: Dynamics, Predictors and Implications on Clinical OutcomesAlexandre Soares Ferreira Junior, Danielle Amanda Niz Alvarez, Larissa da Silva Souza, et al.
Pageof 13